XXXX We and products being improved by TXResistance. transformative TXCanada our reminder throughout that of at you to start team toward mission company's highlight through the today's of within standard we long-term I patients each is I performance, the of of details XXXX progress will growth. the continued we of all sepsis lives provide guide who patient meaningful full today. we make way the for over our We're and year, our resistance, can their On Biosystems priorities, made why TX practiced TX sustained a for commitment questions-and-answers. fourth our is guidance our and panels pandemic improve call, to want progress Biosystems usage the I our remarks, and saved some customers threat quarter results diagnostics and strong antibiotic the before year for aware exists. outcomes, to for of their pathogens, the and the thanking Thank and patients then update lives our of medicine the believe for closing show by joining fundamentally the XXXX resilience I the open care the detection will This priorities many of unwavering the TXBacteria, call our us financial the sepsis-causing reduce John to XXXX Sprague, drive serve. on will turn to around review change success. call become Last and world.
quarter, including fourth product revenue Biosystems' XXX% the $X.X the and million, XXX%, prior total growth to year million, team $X.X period. During of representing generated of compared of revenue TX respectively, the
product total generated highs of compared the representing XXXX, full Each we $XX.X million, record $XX.X the the represented prior year XXX%, including respectively, of growth million, For of revenue to of financial company. revenue accomplishments those XXX% for year. and
cultures $XX and the improved risk matters, organization. billion. require drive in days was it the that molecular at steadfast XXXX, We for Health patients to diagnostic is XXX,XXX or take XX% extremely multiple year. of true Americans achieve the Board to across XXXX, the and costs economic The our is better post-culture product commitment operating related scaled of necessary sepsis Leadership samples Positive is technology, Despite manufacturing, US run to our of patients probability-based strengthened are medicine. tool Throughout company, and pipeline each we of may ensure a clinical mission stay in pathogens one advanced Services that of such more five can Team, that our optimal Directors. pandemic, XX% To to standard staggering, for further to We precision on adoption estimated Human of sepsis the the our current antithesis is a used protocols hospitals relies and positive Senior to to significantly facilities protocols our antifungals. skilled balance cases. sepsis specimen. reduced maintained all our We're our of only hospitalization, nearly sheet. tests. the to sepsis-causing of and as to the our is changes than as cost number Department well the one The and notoriously rely and are toss, sepsis detection insensitive, hour We added rapid critical successful. no focus mortality of human care for on cultures In As broad to of treatment back there X%. each fact the blood claims lives are of and rate of to up look clinical and at of complicate the experience made sepsis made care critical pathogens sepsis. sepsis-causing across as patients, factors delayed The we diagnostic administer by products on commercial deep and get many standard our nearly detect antibiotics year their cost nursing part coin empiric, the blood growth of This in as than increased diversity care.
faster current of the to has the able care enabling that just five hours pathogens standard FDA-cleared only three is, within blood blood, is culture-independent directly to TX five first by change the hours. therapy Biosystems detect sepsis-causing targeted to products to whole aim in hours from draw. Our hours three of
accelerating early and attest set of detection three I intended to sepsis-causing rapid business, In survivor, improving sepsis sales, priorities XXXX, and our a can to strengthen our corporate our operations pathogens. treatment we pipeline. appropriate the personally value our of As advancing
bolters our revenue. which to from XX% bolstered priority, building As was priorities tests, with progress year. - revenue of while we enter sales our we sales, total XXXX product focus of on accelerating Starting three our continue represented these will on XXXX, last by corporate first our TXSARS-CoV-X
saw a decision would a lay important risk our is critical sepsis a of sepsis-focused the remember, are foundation a long-term with hospitalized hospital to for decision high to the microbiology develop users to believed of need products, our company. launch our and COVID-XX. intended products. that It tests growth a and COVID-XX of COVID-XX sepsis test ill We sepsis. We critically between patients quality link the We for labs, diagnostic and molecular strategic
microbiology our than installed revenue significantly US to XXXX, US XXXX States labs, the compared microbiology US half increase hospital installed believed instruments of of to including TXDx within in the labs Finally, by Total We our instruments XXX% sold second hospitals. product the XX we and base. during prior TXDx we in the year. could XX doubled United which more base increased
currently are COVID-XX run of for an While $XXX,XXX being the used rate testing, exiting the fourth XX annualized new at XXXX. quarter instruments of
that panels. of have initial ease. sales when sepsis and our process will COVID we targets these our the strategically during evaluate during to from sepsis our line day game these customers designed expectation facilitate this new US We and adoption to sepsis everything ensure to will stated, to was hospitals transition they in were begin pressures our XXXX with instrument TXDx testing decline pre-screened throughout COVID-XX our one, done plan we testing to commitments to with COVID-XX in accounts the Simply sepsis year. Because was products obtain
XXXX panels bacterial of XXXX, throughout from for and respectively. fourth infections, annualized legacy test at XXXX continued the TXBacteria to for both US $XX,XXX exiting TXCanada, to utilization utilization $XX,XXX and increase infections sepsis beginning sepsis increased fungal among the instrument XX% installed Our test the base our our In by quarter. approximately
to sepsis instrument priorities our commercial to a and Transitioning or sold to TXDx installed One, have three, that Two, legacy utilization transition XXXX. in into XXXX the the For of sepsis second key testing. US part three top base from XXXX, COVID-XX critical half objective performance sold strategy testing our we test and instruments in COVID-XX installed during instruments set to indicators. XXXX of were sepsis expand commercial is increase our for from to hospitals base.
of the the to of team. Driving which team conversations from commercial new our COVID-XX schedule. and has commercial requires right to accounts and adoption right related further platform initiated testing Our customers management, is transitioning already sepsis strategy sepsis ahead with
Chief and sales team US as Sales we In of During XXXX, of end Heads and Operations. of US the the Service Commercial well and Marketing expect XXXX, March. our Officer rebuild as named by to Heads Customer we of the complete
hospital, to hospital including sale executive Our decision-makers Account includes hospitals. required whole a Regional Managers selling representatives made comprehensive departments. clinical that sell effort the is US on sepsis into which the laboratory to from leadership, and generally typically committee, sepsis requires the technology A
of develop generating laboratory leaders, on the community of her Laboratory use lead has and that raise Medical collaborative from our Medicine we programs and creation Dr. recently our products a Leadership hired TX medical will key at lead community. data, with educating Dr. as leadership extensive visibility within awareness pleased in as Ahuja relationships Biosystems Affairs professional of to and significant development clinical will products. the Becton health the Biosystems' relationships on roles the education laboratory economic of Dickinson. TX will clinicians to as Medical that experience Clinical are Officer, the through focusing diagnostic clinical of as She also she and opinion and expert, of maintain a and her the confident Scientific We announce associations. brings visibility Chief and TX teams increase Biosystems' value Advisory We're Board help Senior prior Ahuja Aparna raise well
resulted our headcount our savings structure, initiatives which business, operations. to our Early in implemented real across estate we second XXXX, the in footprint. reductions priority, cost cost Moving and improving in
with product We progress through initiatives gross are in at of reductions of making cost goods. margins improving a aimed number
on also pandemic, in to overhead volume customers a with throughout formed increases the our XXXX, partnerships uninterrupted believe increased beneficial manufacturing we fourfold future. saw key demand. meet products suppliers, which To had unit we to during will the and significant maintain favorable in We which absorption supply be scaled our strategic of we impact
common the gross Finally, we terms to of margins. prioritize our we by continue we sale In stock, sheet facility $XX.X renegotiated strengthen the raising in through and of XXXX, will CRG. million with product improvement credit balance the
decision for to to virus new our made third detect March, significant SARS-CoV-X, our test responsible product priority, a the the In XXXX. progress We made Moving develop is to on our infections. we COVID-XX that during advancing pipeline pipeline.
United on screen variants analysis. subsequently sequence emergency of all virus started developed alignments team Africa identified less when our capable currently of the in not months. use was launched determined diagnostic molecular including variants, we that product We and XX.XX% panel panel identified in radar South with under the authorization this Kingdom, quality silico that and based TXSARS-CoV-X our year, Brazil, in a than test three on the along high TXSARS-CoV-X those is and detecting SARS-CoV-X guidelines While FDA
milestone-based the XXXX. by the under programs BARDA or prioritize government product development in to late contract continue We awarded US
a next-generation total new available a reminder, developing panel. contract $XX under BARDA and focused products, million. biothreat panel As funding instrument, to comprehensive a the sepsis three And the we're on up is
designed next lower cover times at current turnaround to designed to designed yet whole The result. and Our automated XX% detect blood random instrument a is blood generation sample. is all an increased be comprehensive of to species. fully per also will pathogens infections TXDx more being from access, than of instrument, single up and is detect like XXX to number borne sepsis faster our provide The panel instrument a cost reportable
third have a be We In XXXX million of met whole pathogens all a the options. option the disrupt quarter The progress and new biothreat BARDA panel panel single exercise than antibiotic culture first valued biothreat the base the completed $XX.X BARDA to during in test phase highly-sensitive single-patient The resistance milestones. workflow this directed the XXXX multiple led threats believe standard to traditional turnaround and of three is has sample. identified contract blood sepsis potential by funding. CDC a blood use detect one hours. designed a and phase less and includes contracts the from designed a from blood in base the addition is of panel blood to The test. panel comprehensive six all This become time October of sample We care. to totally borne to a to in
and contract budget. We of the and schedule operating under continue to of ahead meet the milestones are
quarter Now, I'll the call detail over turn Sprague John to financials. the fourth to
